Pediatrix Medical Group, INC. (MD) — SEC Filings

Q: What are the key financial highlights for Pediatrix Medical Group, INC.?

Key financial highlights for Pediatrix Medical Group, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Pediatrix Medical Group, INC.?

Key executives at Pediatrix Medical Group, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Pediatrix Medical Group, INC. stock?

Risk factors for Pediatrix Medical Group, INC. (MD) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Pediatrix Medical Group, INC.?

Forward-looking statements and predictions from Pediatrix Medical Group, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Pediatrix Medical Group, INC.. Recent ARS filing on Mar 27, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Pediatrix Medical Group, INC. on SEC EDGAR

Overview

Pediatrix Medical Group, INC. (MD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Mar 27, 2026: Pediatrix Medical Group, Inc. filed a DEFA14A on March 27, 2026, which includes additional definitive proxy soliciting materials. The filing contains 3 documents, including the main DEFA14A filing and two graphic files. The company's mailing and business address is 1301 Concord Terrace, Sunrise, FL

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 27 neutral, 1 mixed. The dominant filing sentiment for Pediatrix Medical Group, INC. is neutral.

Filing Type Overview

Pediatrix Medical Group, INC. (MD) has filed 1 ARS, 1 DEFA14A, 6 10-Q, 11 8-K, 2 DEF 14A, 2 10-K, 2 SC 13G, 6 SC 13G/A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (31)

ARS Filing — ARS · Mar 27, 2026
Pediatrix Medical Group Files Additional Proxy Materials — DEFA14A · Mar 27, 2026 Risk: low
Pediatrix Medical Group, Inc. filed a DEFA14A on March 27, 2026, which includes additional definitive proxy soliciting materials. The filing contains 3 document
Pediatrix Swings to Profit on Impairment Absence, Cash Surges — 10-Q · Nov 3, 2025 Risk: medium
Pediatrix Medical Group, Inc. (MD) reported a significant turnaround for the nine months ended September 30, 2025, with net income reaching $131.705 million, a
Pediatrix Medical Group Files 8-K — 8-K · Aug 18, 2025 Risk: low
Pediatrix Medical Group, Inc. filed an 8-K on August 18, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure,
Pediatrix Q2 Revenue Dips Amidst Healthcare Headwinds — 10-Q · Aug 5, 2025 Risk: medium
Pediatrix Medical Group, Inc. reported patient service revenue of $460.1 million for the three months ended June 30, 2025, a decrease from $467.2 million in the
Pediatrix Medical Group Announces Director Changes — 8-K · Jul 1, 2025 Risk: medium
Pediatrix Medical Group, Inc. announced on July 1, 2025, the departure of Director Mark J. Ordan and the appointment of Dr. Charles R. V. Hall as a new director
Pediatrix Medical Group Files 8-K on Shareholder Vote — 8-K · May 8, 2025 Risk: low
On May 8, 2025, Pediatrix Medical Group, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders
Pediatrix Medical Group Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
Pediatrix Medical Group, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the firs
Pediatrix Medical Group Enters Material Definitive Agreement — 8-K · Apr 18, 2025 Risk: medium
On April 15, 2025, Pediatrix Medical Group, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement'
Pediatrix Medical Group Executive Compensation Details — DEF 14A · Mar 28, 2025 Risk: low
Pediatrix Medical Group, Inc. filed a DEF 14A on March 28, 2025, detailing executive compensation and corporate governance matters. The filing includes informat
Pediatrix Medical Group Files 2024 10-K — 10-K · Feb 20, 2025 Risk: medium
Pediatrix Medical Group, Inc. filed its 2024 10-K on February 20, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as ME
Pediatrix Medical Group Announces Board and Executive Changes — 8-K · Jan 14, 2025 Risk: medium
Pediatrix Medical Group, Inc. announced on January 12, 2025, changes in its board of directors and executive compensation. Specifically, the company reported th
Pediatrix Medical Group Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
Pediatrix Medical Group, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulat
Pediatrix Medical Group Announces Board Changes — 8-K · Dec 5, 2024 Risk: low
Pediatrix Medical Group, Inc. announced on November 29, 2024, the departure of director Mark J. Ordan and the appointment of two new directors, David M. Smith a
SC 13G Filing — SC 13G · Nov 13, 2024
Pediatrix Medical Group Files Q3 2024 10-Q — 10-Q · Nov 1, 2024 Risk: low
Pediatrix Medical Group, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the
SC 13G/A Filing — SC 13G/A · Oct 31, 2024
Pediatrix Medical Group Files Q2 2024 10-Q — 10-Q · Aug 6, 2024 Risk: medium
Pediatrix Medical Group, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the secon
Pediatrix Medical Group Announces Leadership Changes — 8-K · Jun 17, 2024 Risk: medium
Pediatrix Medical Group, Inc. announced on June 17, 2024, the departure of its Chief Medical Officer, Dr. Mark L. Callahan, effective June 14, 2024. The company
SC 13G/A Filing — SC 13G/A · Jun 10, 2024
Pediatrix Medical Group Files 8-K — 8-K · May 30, 2024 Risk: low
Pediatrix Medical Group, Inc. filed an 8-K on May 30, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not cont
Pediatrix Medical Group Files 8-K on Shareholder Votes — 8-K · May 9, 2024 Risk: low
Pediatrix Medical Group, Inc. filed an 8-K on May 9, 2024, to report on matters submitted to a vote of its security holders. The filing does not detail the spec
Pediatrix Medical Group, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk:
Pediatrix Medical Group, Inc. (MD) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Pediatrix Medical Group, Inc. filed a 10-Q report for the period
Pediatrix Medical Group Enters Material Definitive Agreement — 8-K · Apr 25, 2024 Risk: medium
On April 19, 2024, Pediatrix Medical Group, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement,
Pediatrix Medical Group, Inc. Files Definitive Proxy Statement — DEF 14A · Mar 28, 2024 Risk:
Pediatrix Medical Group, Inc. (MD) filed a Proxy Statement (DEF 14A) with the SEC on March 28, 2024. Pediatrix Medical Group, Inc. filed a Definitive Proxy Stat
Pediatrix Medical Group, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 20, 2024 Risk: medium
Pediatrix Medical Group, Inc. (MD) filed a Annual Report (10-K) with the SEC on February 20, 2024. Pediatrix Medical Group, Inc. filed its annual report on Form
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
Vanguard Amends Pediatrix Stake to 9.0% as of Dec 29, 2023 — SC 13G/A · Feb 13, 2024 Risk: low
The Vanguard Group, a major investment firm, filed an amendment (SC 13G/A) on February 13, 2024, updating its ownership in Pediatrix Medical Group Inc. As of De
EARNEST Partners Updates Passive Stake in Pediatrix Medical Group — SC 13G/A · Feb 12, 2024 Risk: low
EARNEST Partners, LLC, a Delaware-based investment advisor, filed an amended Schedule 13G/A on February 12, 2024, indicating their ownership in Pediatrix Medica
Dimensional Fund Advisors Reports 5.5% Stake in Pediatrix Medical — SC 13G · Feb 9, 2024 Risk: low
Dimensional Fund Advisors LP, a major investment firm, reported on February 9, 2024, that it holds 4,683,927 shares of Pediatrix Medical Group Inc. (formerly ME
BlackRock Lowers Pediatrix Stake to 8.4% as of Dec 31, 2023 — SC 13G/A · Jan 22, 2024
BlackRock Inc. filed an amended Schedule 13G/A on January 22, 2024, indicating a change in its ownership of Pediatrix Medical Group, Inc. common stock as of Dec

Risk Profile

Risk Assessment: Of MD's 23 recent filings, 0 were flagged as high-risk, 11 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Pediatrix Medical Group, INC.'s most recent 10-Q filing (Nov 3, 2025):

Revenue: $1.420B
Net Income: $131.705M
EPS: $1.53
Debt-to-Equity: N/A
Cash Position: $340.059M
Operating Margin: 11.27%
Total Assets: $1.70B
Total Debt: N/A

Key Executives

Mark J. Ordan
Dr. Charles R. V. Hall
David M. Smith
David L. Williams
Dr. Mark L. Callahan
Dr. Jennifer L. Stone
Ms. Pamela G. Bentley
Mr. David L. Osborne
December 29, 2023
February 9, 2024

Industry Context

Pediatrix Medical Group operates in the highly competitive healthcare services sector, specifically focusing on physician services. The industry is characterized by evolving reimbursement models, increasing regulatory scrutiny, and a growing demand for specialized pediatric care. Consolidation among providers and shifts towards value-based care are key trends impacting companies like Pediatrix.

Top Tags

Pediatrix Medical Group (4) · 10-Q (4) · institutional-ownership (4) · financials (3) · healthcare (3) · Healthcare Services (2) · Revenue Decline (2) · 10-Q Analysis (2) · 8-K (2) · shareholder-vote (2)

Key Numbers

Net Income: $131.705M — Nine months ended Sep 30, 2025, a swing from -$129.549M loss in 2024
Net Revenue: $1.420B — Nine months ended Sep 30, 2025, down from $1.511B in 2024
Cash and Cash Equivalents: $340.059M — As of Sep 30, 2025, up from $229.940M at Dec 31, 2024
Income from Operations: $160.019M — Nine months ended Sep 30, 2025, a significant improvement from -$108.004M loss in 2024
Revenue Decline: 5.99% — Nine months ended Sep 30, 2025, compared to the same period in 2024
Net Cash Provided by Operating Activities: $156.989M — Nine months ended Sep 30, 2025, up from $73.563M in 2024
Shares Outstanding: 85,877,386 — As of October 30, 2025
Net Patient Service Revenue from Contracted/Government Payors: 95% — For the nine months ended Sep 30, 2025
Retained Deficit: $116.835M — As of September 30, 2025
Commission File Number: 001-12111 — Identifies the company's filing with the SEC
IRS Employer Identification No.: 26-3667538 — Company's tax identification number
Patient Service Revenue (Q2 2025): $460.1M — Decreased from $467.2 million in Q2 2024
Patient Service Revenue (YTD Q2 2025): $915.2M — Decreased from $930.1 million in YTD Q2 2024
Interest Rate: 5.375% — Unsecured Senior Notes due 2030
Revolving Credit Facility Availability: $250.0M — Available as of June 30, 2025

Forward-Looking Statements

{"claim":"Vanguard will maintain a significant stake in Pediatrix Medical Group Inc. for the foreseeable future.","entity":"The Vanguard Group","targetDate":"2025-12-31","confidence":"high"}
{"claim":"EARNEST Partners, LLC will maintain a passive investment strategy in Pediatrix Medical Group, Inc.","entity":"EARNEST Partners, LLC","targetDate":"Next 12 months","confidence":"high"}
{"claim":"Dimensional Fund Advisors LP will maintain or slightly increase its passive stake in Pediatrix Medical Group Inc. over the next year.","entity":"Dimensional Fund Advisors LP","targetDate":"February 9, 2025","confidence":"medium"}

Related Companies

HCA · TEN · LPNT

Frequently Asked Questions

What are the latest SEC filings for Pediatrix Medical Group, INC. (MD)?

Pediatrix Medical Group, INC. has 31 recent SEC filings from Jan 2024 to Mar 2026, including 11 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of MD filings?

Across 31 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 27 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Pediatrix Medical Group, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Pediatrix Medical Group, INC. (MD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Pediatrix Medical Group, INC.?

Key financial highlights from Pediatrix Medical Group, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for MD?

The investment thesis for MD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Pediatrix Medical Group, INC.?

Key executives identified across Pediatrix Medical Group, INC.'s filings include Mark J. Ordan, Dr. Charles R. V. Hall, David M. Smith, David L. Williams, Dr. Mark L. Callahan and 5 others.

What are the main risk factors for Pediatrix Medical Group, INC. stock?

Of MD's 23 assessed filings, 0 were flagged high-risk, 11 medium-risk, and 12 low-risk.

What are recent predictions and forward guidance from Pediatrix Medical Group, INC.?

Recent forward-looking statements from Pediatrix Medical Group, INC. include guidance on {"claim":"Vanguard will maintain a significant stake in Pediatrix Medical Group Inc. for the foreseeable future.","entit and 2 other predictions.